Treos Bio to Present New Clinical Data at ASCO 2024 and Participate in Upcoming Scientific Conferences
LONDON, April 24, 2024 (GLOBE NEWSWIRE)– Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that results of OBERTO-301 Phase II clinical trial will be presented at American Society of Medical Oncology (ASCO) 2024 Annual Meeting. Management will be participating in the following scientific and medical conferences.